Antimicrobial Peptides From Amphibian Skin as Potential Therapeutics
Main Article Content
Abstract
Background: Multidrug-resistant bacterial infections are a growing challenge in tertiary-care hospitals, particularly where antimicrobial pressure is high and treatment options are limited. Amphibian skin secretions contain antimicrobial peptides that may provide novel leads for anti-infective development. Objective: This study aimed to isolate peptide-containing fractions from amphibian skin secretions and evaluate their in vitro antibacterial, antibiofilm, safety, and stability profiles against multidrug-resistant clinical isolates. Methods: An experimental laboratory-based study was conducted using 87 non-duplicate multidrug-resistant isolates, including MRSA, ESBL-producing Escherichia coli, ESBL-producing Klebsiella pneumoniae, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii. Amphibian skin secretions were processed into crude extract and purified by RP-HPLC to obtain two active fractions, AMP-1 and AMP-2. Antibacterial activity was assessed using MIC and MBC testing, time–kill kinetics, biofilm inhibition and disruption assays, hemolysis testing, mammalian-cell viability screening, and short-term serum stability assessment. Results: AMP-1 showed the strongest antibacterial profile, with median MICs of 4 µg/mL against MRSA, 8 µg/mL against ESBL-producing E. coli, and 16 µg/mL against carbapenem-resistant P. aeruginosa. MBCs were generally one dilution above MIC values. AMP-1 produced concentration-dependent killing against MRSA, inhibited biofilm formation more effectively than it disrupted mature biofilm, and showed lower hemolysis than AMP-2 at matched concentrations. AMP-1 retained 76% activity after 4 hours in 25% serum, compared with 68% for AMP-2. Conclusion: Amphibian-derived AMP fractions, particularly AMP-1, demonstrated promising in vitro activity and preliminary selectivity against MDR pathogens, supporting further peptide characterization, optimization, formulation development, and preclinical validation
Article Details
Section

This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
1. Rollins-Smith LA. The importance of antimicrobial peptides (AMPs) in amphibian skin defense. Dev Comp Immunol. 2023;142:104657. doi:10.1016/j.dci.2023.104657.
2. Chen X, Lin H, Zhang Y, et al. Peptides isolated from amphibian skin secretions with emphasis on antimicrobial peptides. Toxins (Basel). 2022;14(10):722. doi:10.3390/toxins14100722.
3. Xuan J, Feng W, Wang J, et al. Antimicrobial peptides for combating drug-resistant bacterial infections. Drug Resist Updat. 2023;100954. doi:10.1016/j.drup.2023.100954.
4. Wiegand I, Hilpert K, Hancock REW. Agar and broth dilution methods to determine the MIC of antimicrobial substances. Nat Protoc. 2008;3:163-175. doi:10.1038/nprot.2007.521.
5. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions. Clin Microbiol Infect. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x.
6. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389-395. doi:10.1038/415389a.
7. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin. Proc Natl Acad Sci U S A. 1987;84(15):5449-5453. doi:10.1073/pnas.84.15.5449.
8. Hancock REW, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24(12):1551-1557. doi:10.1038/nbt1267.
9. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3(3):238-250. doi:10.1038/nrmicro1098.
10. Conlon JM. Structural diversity and species distribution of host-defense peptides in frog skin secretions. Cell Mol Life Sci. 2011;68(13):2303-2315. doi:10.1007/s00018-011-0720-8.
11. Mukhopadhyay S, Prasad ASB, Mehta CH, Nayak UY. Antimicrobial peptide polymers: no escape to ESKAPE pathogens—a review. World J Microbiol Biotechnol. 2020;36(9):131. doi:10.1007/s11274-020-02907-1.
12. D’Andrea LD, Romanelli A. Temporins: multifunctional peptides from frog skin. Amino Acids. 2023;55:123-134. doi:10.1007/s00726-023-03210-z.
13. Yin S, Wang Y, Yang X. Amphibian-derived wound healing peptides: chemical treasure trove. Front Pharmacol. 2023;14:1120228. doi:10.3389/fphar.2023.1120228.
14. Pletzer D, Hancock REW. Antibiofilm peptides: potential as broad-spectrum agents. J Bacteriol. 2016;198(19):2572-2578. doi:10.1128/JB.00017-16.
15. Dostert M, Trimble MJ, Hancock REW. Antibiofilm peptides: overcoming biofilm-related treatment failure. RSC Adv. 2021;11:2718-2728. doi:10.1039/D0RA09593J.